AR090726A1 - Vacunas y procedimientos para tratar la enfermedad de lyme en perros - Google Patents

Vacunas y procedimientos para tratar la enfermedad de lyme en perros

Info

Publication number
AR090726A1
AR090726A1 ARP130101267A ARP130101267A AR090726A1 AR 090726 A1 AR090726 A1 AR 090726A1 AR P130101267 A ARP130101267 A AR P130101267A AR P130101267 A ARP130101267 A AR P130101267A AR 090726 A1 AR090726 A1 AR 090726A1
Authority
AR
Argentina
Prior art keywords
vaccines
dogs
procedures
disease
immunogenic composition
Prior art date
Application number
ARP130101267A
Other languages
English (en)
Inventor
M Lohse Robert
F M Meeus Patrick
J Millership Jason
Xu Zach
Original Assignee
Zoetis Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Llc filed Critical Zoetis Llc
Publication of AR090726A1 publication Critical patent/AR090726A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición inmunógena que comprende un fragmento antigénico de proteína OspA de Borrelia burgdorferi y una proteína quimérica que contiene fragmentos antigénicos de diferentes filotipos de proteína OspC de Borrelia burgdorferi. También vacunas que incorporan la composición inmunógena de la presente, así como procedimientos para prevenir la enfermedad de Lyme en perros y/o proteger perros de la enfermedad de Lyme usando las vacunas.
ARP130101267A 2012-04-18 2013-04-17 Vacunas y procedimientos para tratar la enfermedad de lyme en perros AR090726A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261635031P 2012-04-18 2012-04-18

Publications (1)

Publication Number Publication Date
AR090726A1 true AR090726A1 (es) 2014-12-03

Family

ID=48193279

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101267A AR090726A1 (es) 2012-04-18 2013-04-17 Vacunas y procedimientos para tratar la enfermedad de lyme en perros

Country Status (10)

Country Link
EP (1) EP2838555A2 (es)
JP (1) JP2015514776A (es)
CN (1) CN104379164A (es)
AR (1) AR090726A1 (es)
AU (1) AU2013249229A1 (es)
BR (1) BR112014025740A2 (es)
CA (1) CA2870179C (es)
EA (1) EA201491668A1 (es)
UY (1) UY34745A (es)
WO (1) WO2013158818A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10086057B2 (en) 2014-10-08 2018-10-02 Virginia Commonwealth University Stage specific diagnostic antigens, assay and vaccine for lyme disease
AU2018379121B2 (en) * 2017-12-04 2024-05-02 Intervet International B.V. Canine lyme disease vaccine
CN110483624B (zh) * 2019-08-22 2021-02-09 中国疾病预防控制中心传染病预防控制所 伽氏疏螺旋体OspA蛋白C端肽段及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567042A (en) 1983-06-15 1986-01-28 American Home Products Corporation Inactivated canine coronavirus vaccine
US4567043A (en) 1983-06-15 1986-01-28 American Home Products Corporation (Del.) Canine corona virus vaccine
US6872550B1 (en) 1991-07-11 2005-03-29 Baxter Vaccine Ag Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
DE69229476T2 (de) * 1991-08-15 2000-03-16 Smithkline Beecham Biolog Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe
CA2332570C (en) 1998-07-31 2009-12-08 Gundersen Lutheran Medical Foundation, Inc. Uses of the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein c (ospc) as vaccine
US20110262475A1 (en) * 2008-05-02 2011-10-27 Earnhart Christopher G Lyme disease vaccine
WO2010132758A2 (en) * 2009-05-14 2010-11-18 Gomes-Solecki Maria J Ospc-based diagnostic test for lyme disease
AU2011317105B2 (en) * 2010-10-20 2018-04-05 Virginia Commonwealth University Polyvalent chimeric OspC vaccinogen and diagnostic antigen

Also Published As

Publication number Publication date
UY34745A (es) 2013-11-29
CA2870179C (en) 2018-09-04
AU2013249229A1 (en) 2014-10-23
EA201491668A1 (ru) 2015-08-31
WO2013158818A2 (en) 2013-10-24
CA2870179A1 (en) 2013-10-24
JP2015514776A (ja) 2015-05-21
EP2838555A2 (en) 2015-02-25
CN104379164A (zh) 2015-02-25
BR112014025740A2 (pt) 2017-07-04
WO2013158818A3 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
IL267997A (en) Preparations, formulations and methods for treating eye diseases
MX340739B (es) Quimeras ospa y su uso en vacunas.
BR112012005225B8 (pt) Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente
CO7151522A2 (es) Proteínas de fusión de interleuquina-10 y usos de las mismas
CO7160093A2 (es) Anticuerpos anti-egfr y usos de los mismos
IL257057A (en) Biologically active peptides derived from soy for use in preparations and methods for wound healing, tissue engineering and regenerative medicine
MX2015011199A (es) Agentes terapéuticos de csf1.
BR112014023937A2 (pt) composição farmacêutica, agente farmacêutico de combinação e método de tratamento
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
EP3845241A8 (en) Long lasting effect of new botulinum toxin formulations
DOP2013000235A (es) Proteínas de fusión y vacunas de combinación que comprenden proteína e y pilina a de haemophilus influenzae.
MX2019003004A (es) Composiciones para inmunizacion contra staphylococcus aureus.
BR112016013109A2 (pt) anticorpos de anti-siglec-8 e métodos de seu uso
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
IN2015DN02729A (es)
BR112018013756A2 (pt) suturas cirúrgicas para aumentar a pele
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
UA114286C2 (uk) Спосіб лікування staphylococcus aureus
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
AR094851A1 (es) COMPUESTOS BICíCLICOS COMO AGONISTAS DE S1P₁
BR112015016033A8 (pt) composições farmacêuticas para tratamento de infecções por bactérias, e seus usos
BR112015001843A2 (pt) dispositivo médico, composição de matriz biodegradável e método para tratar um paciente.
AR090726A1 (es) Vacunas y procedimientos para tratar la enfermedad de lyme en perros
WO2014018274A8 (en) Compositions comprising chimeric ospa molecules and methods of use thereof
DK3003363T3 (da) Immunogen sammensætning til anvendelse i terapi

Legal Events

Date Code Title Description
FB Suspension of granting procedure